AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11031393 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir hydrochloride (1 g 3 times daily) for 7 days
Number of subjects: 597
Study 11031393 — intervention group
Group type: COMPARATOR
Intervention: Famciclovir (500 mg 3 times daily) for 7 days
Number of subjects: 597
Study 11031393 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir hydrochloride
Number of subjects: 597
Study 11031393 — intervention group
Group type: COMPARATOR
Intervention: Famciclovir
Number of subjects: 597
Study 8741812 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 39
Study 8741812 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 39
Study 1424650 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidermal growth factor (EGF)
Number of subjects: 104
Study 1424650 — intervention group
Group type: COMPARATOR
Intervention: Placebo (drug vehicle)
Number of subjects: 104
Study 3937820 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 50 micrograms
Number of subjects: 32
Study 3937820 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms
Number of subjects: 32
Study 3937820 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 300 mg
Number of subjects: 32
Study 30035341 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP‐O
Number of subjects: 21
Study 29363159 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic games programme (EG)
Number of subjects: 111
Study 29363159 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 111
Study 26964554 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure therapy (CPAP) for 24 weeks
Number of subjects: 162
Study 26964554 — intervention group
Group type: COMPARATOR
Intervention: Control group (AHI < 5 and AHI 5-15)
Number of subjects: 162
Study 25410198 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 0
Study 25410198 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 0
Study 25410198 — intervention group
Group type: COMPARATOR
Intervention: Usual care activity
Number of subjects: 0
Study 22722504 — intervention group
Group type: EXPERIMENTAL
Intervention: ziprasidone 40 to 80 mg/d
Number of subjects: 0
Study 22722504 — intervention group
Group type: EXPERIMENTAL
Intervention: ziprasidone 120 to 160 mg/d
Number of subjects: 0
Study 22722504 — intervention group
Group type: EXPERIMENTAL
Intervention: ziprasidone 40 to 160 mg/d
Number of subjects: 0
Study 22722504 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 20147715 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty plus stent graft
Number of subjects: 190
Study 20147715 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty alone
Number of subjects: 190
Study 17591032 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine, didanosine and efavirenz
Number of subjects: 40
Study 15501922 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise (20-min treadmill at 65-70% peak oxygen consumption)
Number of subjects: 0
Study 15501922 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise
Number of subjects: 0
Study 12053117 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual-processing speed assessment
Number of subjects: 173
Study 12053117 — intervention group
Group type: COMPARATOR
Intervention: Everyday Problems Test
Number of subjects: 173
Study 12053117 — intervention group
Group type: COMPARATOR
Intervention: Observed Tasks of Daily Living
Number of subjects: 173
Study 9469359 — intervention group
Group type: COMPARATOR
Intervention: BEP/EP chemotherapy regimen (bleomycin, etoposide, and cisplatin)
Number of subjects: 380
Study 9469359 — intervention group
Group type: EXPERIMENTAL
Intervention: BOP/VIP-B chemotherapy regimen (bleomycin, vincristine, cisplatin / etoposide, ifosfamide, cisplatin, and bleomycin)
Number of subjects: 380
Study 9469359 — intervention group
Group type: COMPARATOR
Intervention: BEP/EP
Number of subjects: 380
Study 9469359 — intervention group
Group type: EXPERIMENTAL
Intervention: BOP/VIP-B
Number of subjects: 380
Study 7665441 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH), 10 mg single dose
Number of subjects: 0
Study 7665441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2470768 — intervention group
Group type: EXPERIMENTAL
Intervention: Video instruction
Number of subjects: 150
Study 2470768 — intervention group
Group type: COMPARATOR
Intervention: Personal tuition by a pharmacist
Number of subjects: 150
Study 2470768 — intervention group
Group type: COMPARATOR
Intervention: Manufacturer's package insert
Number of subjects: 150
Study 778483 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran
Number of subjects: 31
Study 778483 — intervention group
Group type: EXPERIMENTAL
Intervention: Small doses of s.c. heparin
Number of subjects: 31
Study 778483 — intervention group
Group type: COMPARATOR
Intervention: Control (no therapy)
Number of subjects: 31
Study 30347011 — intervention group
Group type: EXPERIMENTAL
Intervention: Active DLPFC stimulation
Number of subjects: 16
Study 30347011 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 16
Study 28224289 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontalis suspension using Gore-Tex through a skin crease incision (group I)
Number of subjects: 13
Study 28224289 — intervention group
Group type: COMPARATOR
Intervention: Frontalis suspension using Gore-Tex through supraciliary incisions (group II)
Number of subjects: 13
Study 25886787 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-Valent Pneumococcal Conjugate Vaccine
Number of subjects: 0
Study 24002213 — intervention group
Group type: EXPERIMENTAL
Intervention: CB formulation (Curcuma longa and Boswellia serrata extracts) 500 mg twice a day
Number of subjects: 30
Study 24002213 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 100 mg twice a day
Number of subjects: 30
Study 21385602 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg in 12 h)
Number of subjects: 11
Study 21385602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 21385602 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise in 30°C
Number of subjects: 11
Study 21385602 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 11
Study 19472440 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of acetylsalicylic acid + paracetamol + caffeine
Number of subjects: 1734
Study 19472440 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to 50% pain relief (primary endpoint)
Number of subjects: 1734
Study 19472440 — intervention group
Group type: EXPERIMENTAL
Intervention: Sum of pain intensity difference
Number of subjects: 1734
Study 19472440 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of pain intensity to 10 mm on visual analog scale
Number of subjects: 1734
Study 19472440 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain reduction by 50% within 1 hour after drug intake
Number of subjects: 1734
Study 19472440 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to be pain-free
Number of subjects: 1734
Study 18043308 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month aerobic exercise training programme (four times/week, 45-60 min/session)
Number of subjects: 60
Study 14513922 — intervention group
Group type: EXPERIMENTAL
Intervention: 52 g tryptophan depleting amino-acid drink
Number of subjects: 20
Study 14513922 — intervention group
Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 20
Study 11071421 — intervention group
Group type: EXPERIMENTAL
Intervention: ECHO36 (lemon-lime ECHO with 36 mEq/L NaCl)
Number of subjects: 18
Study 11071421 — intervention group
Group type: EXPERIMENTAL
Intervention: ECHO18 (lemon-lime ECHO with 18 mEq/L NaCl)
Number of subjects: 18
Study 11071421 — intervention group
Group type: COMPARATOR
Intervention: Water (lime colored water)
Number of subjects: 18
Study 11071421 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lemon-lime placebo)
Number of subjects: 18
Study 11071421 — intervention group
Group type: EXPERIMENTAL
Intervention: ECHO36
Number of subjects: 18
Study 11071421 — intervention group
Group type: EXPERIMENTAL
Intervention: ECHO18
Number of subjects: 18
Study 11071421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 11071421 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 18
Study 9168215 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-down tilt position
Number of subjects: 34
Study 9168215 — intervention group
Group type: COMPARATOR
Intervention: Horizontal position
Number of subjects: 34
Study 1729974 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper extremity aerobic exercise program (3 times a week for 20 minutes at 70%-75% heart rate reserve)
Number of subjects: 10
Study 1729974 — intervention group
Group type: COMPARATOR
Intervention: Non-exercised control group (N=10)
Number of subjects: 10
Study 3777103 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential block placement during the Space Visualization test (SV)
Number of subjects: 71
Study 3777103 — intervention group
Group type: EXPERIMENTAL
Intervention: Space Visualization (SV) adjusted scores
Number of subjects: 71
Study 31641005 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate for 12 hours after diagnosis
Number of subjects: 2089
Study 31641005 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate for 24 hours after diagnosis
Number of subjects: 2089
Study 29323831 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycling intervention led by a certified instructor for 12 weeks
Number of subjects: 38
Study 29323831 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycling intervention
Number of subjects: 38
Study 29323831 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 26474864 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Fluticasone Furoate (FF)
Number of subjects: 1225
Study 26474864 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Vilanterol (VI)
Number of subjects: 1225
Study 26474864 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of FF and VI (FF/VI)
Number of subjects: 1225
Study 24584918 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg (loading dose)
Number of subjects: 0
Study 24584918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22677458 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-Step peer intervention (PI)
Number of subjects: 151
Study 22677458 — intervention group
Group type: EXPERIMENTAL
Intervention: doctor intervention (DI)
Number of subjects: 151
Study 22677458 — intervention group
Group type: COMPARATOR
Intervention: no intervention (NI)
Number of subjects: 151
Study 22677458 — intervention group
Group type: EXPERIMENTAL
Intervention: inpatient meeting attenders
Number of subjects: 151
Study 22677458 — intervention group
Group type: EXPERIMENTAL
Intervention: post-discharge meeting attenders
Number of subjects: 151
Study 18295212 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (800 microg) administered vaginally
Number of subjects: 140
Study 18295212 — intervention group
Group type: COMPARATOR
Intervention: Suction evacuation (surgical method)
Number of subjects: 140
Study 17301564 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent antiretroviral therapy (8-week off, 8-week on regimen)
Number of subjects: 403
Study 17301564 — intervention group
Group type: COMPARATOR
Intervention: Continuous antiretroviral therapy
Number of subjects: 403
Study 17301564 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent antiretroviral therapy
Number of subjects: 403
Study 15064315 — intervention group
Group type: EXPERIMENTAL
Intervention: SCOT I procedure
Number of subjects: 54
Study 15064315 — intervention group
Group type: EXPERIMENTAL
Intervention: SCOT II procedure
Number of subjects: 54
Study 15064315 — intervention group
Group type: COMPARATOR
Intervention: Bilateral total orchiectomy (BTO)
Number of subjects: 54
Study 15064315 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH agonist
Number of subjects: 54
Study 11586115 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone
Number of subjects: 25
Study 11586115 — intervention group
Group type: COMPARATOR
Intervention: Entacapone
Number of subjects: 25
Study 9505001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 7635414 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 120
Study 7635414 — intervention group
Group type: COMPARATOR
Intervention: Ligation
Number of subjects: 120
Study 2676558 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 0
Study 2676558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 319117 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (120 mg daily for six weeks)
Number of subjects: 208
Study 319117 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (2400 mg daily for six weeks)
Number of subjects: 208
Study 319117 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 208
Study 31515173 — intervention group
Group type: EXPERIMENTAL
Intervention: Patches plus nicotine e‐cigarette
Number of subjects: 1124
Study 31515173 — intervention group
Group type: EXPERIMENTAL
Intervention: Patches plus nicotine‐free e‐cigarette
Number of subjects: 1124
Study 31515173 — intervention group
Group type: COMPARATOR
Intervention: Patches only
Number of subjects: 1124
Study 31183861 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Mallampati classification
Number of subjects: 453
Study 31183861 — intervention group
Group type: EXPERIMENTAL
Intervention: First formant of /i/ (iF1)
Number of subjects: 453
Study 31183861 — intervention group
Group type: EXPERIMENTAL
Intervention: Second formant of /i/ (iF2)
Number of subjects: 453
Study 31183861 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression model including both formants and Mallampati
Number of subjects: 453
Study 31183861 — intervention group
Group type: COMPARATOR
Intervention: Formants alone
Number of subjects: 453
Study 31183861 — intervention group
Group type: COMPARATOR
Intervention: Modified Mallampati alone
Number of subjects: 453
Study 31183861 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice sounds
Number of subjects: 453
Study 28103052 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrients + medication
Number of subjects: 59
Study 28103052 — intervention group
Group type: COMPARATOR
Intervention: Medication only (Control)
Number of subjects: 59
Study 25760127 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional motivational strategy + activation of intention strategy (Intervention Group)
Number of subjects: 0
Study 25760127 — intervention group
Group type: COMPARATOR
Intervention: Traditional motivational strategy (Control Group)
Number of subjects: 0
Study 23574727 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate
Number of subjects: 15
Study 23574727 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 15
Study 21332679 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with intrathecal morphine
Number of subjects: 162
Study 21332679 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 162
Study 19845035 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone (1 or 2 mg)
Number of subjects: 44
Study 16706691 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous irradiation with polychromatic visible and infrared light (480-3400 nm, 95% polarization, 12 J/cm²)
Number of subjects: 0
Study 16706691 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous irradiation with polychromatic visible and infrared light
Number of subjects: 0
Study 16706691 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro irradiation of blood (2.4 J/cm²)
Number of subjects: 0
Study 16706691 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixing irradiated and non-irradiated autologous blood at a volume ratio 1:10
Number of subjects: 0
Study 14995150 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium supplementation (1000 microg/day as Cr yeast)
Number of subjects: 0
Study 14995150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11405578 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of referential cues in emotional messages
Number of subjects: 80
Study 11405578 — intervention group
Group type: COMPARATOR
Intervention: Absence of referential cues in emotional messages
Number of subjects: 80
Study 11405578 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation of referential cues to disambiguate emotional displays
Number of subjects: 80
Study 9163639 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP840 (15 mg b.i.d. for 9.5 days)
Number of subjects: 54
Study 9163639 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP840 (15 and 30 mg single dose)
Number of subjects: 54
Study 9163639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 8354046 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 184
Study 8354046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 6384558 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 (20 ng/kg/min) for 72 hours
Number of subjects: 120
Study 6384558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 30390148 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback Informed Treatment (FIT)
Number of subjects: 166
Study 30390148 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 166
Study 29880245 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccination program
Number of subjects: 142
Study 26859481 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-use therapeutic food (RUTF) - 1 sachet/day for 14 days
Number of subjects: 2202
Study 26859481 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient powder (MNP) - 2 sachets/day for 14 days
Number of subjects: 2202
Study 26859481 — intervention group
Group type: COMPARATOR
Intervention: Control - no supplement
Number of subjects: 2202
Study 25410633 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological online intervention (Deprexis)
Number of subjects: 0
Study 25410633 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control (WLC)
Number of subjects: 0
Study 22155477 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopaminergic medication ON
Number of subjects: 0
Study 22155477 — intervention group
Group type: COMPARATOR
Intervention: No dopaminergic medication OFF
Number of subjects: 0
Study 20460027 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound infiltration with local anaesthetic after CS under regional analgesia
Number of subjects: 1150
Study 20460027 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound infiltration and peritoneal spraying with local anaesthetic after CS under general anaesthesia
Number of subjects: 1150
Study 20460027 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetic and non-steroidal anti-inflammatory cocktail wound infiltration after CS under regional analgesia
Number of subjects: 1150
Study 20460027 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal nerve blocks after regional analgesia
Number of subjects: 1150
Study 20460027 — intervention group
Group type: COMPARATOR
Intervention: Wound infiltration with a mixture of local analgesia and narcotics
Number of subjects: 1150
Study 17215845 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice consumption (concomitantly or 2 hours before fexofenadine administration)
Number of subjects: 0
Study 17215845 — intervention group
Group type: COMPARATOR
Intervention: Fexofenadine
Number of subjects: 0
Study 16713831 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous needle fasciotomy (PNF)
Number of subjects: 166
Study 16713831 — intervention group
Group type: COMPARATOR
Intervention: Limited fasciectomy (LF)
Number of subjects: 166
Study 15164249 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate with E-Lyte supplements (Group 1)
Number of subjects: 187
Study 15164249 — intervention group
Group type: COMPARATOR
Intervention: Oral sodium phosphate without E-Lyte supplements (Group 2)
Number of subjects: 187
Study 10731002 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-arm cranking
Number of subjects: 7
Study 10731002 — intervention group
Group type: COMPARATOR
Intervention: 2-leg cycling
Number of subjects: 7
Study 8777618 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1.2 g daily, divided into three doses for 2 months)
Number of subjects: 36
Study 8777618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 8777618 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 36
Study 1801880 — intervention group
Group type: EXPERIMENTAL
Intervention: BFM Protocol ALL-BFM 81
Number of subjects: 897
Study 1801880 — intervention group
Group type: COMPARATOR
Intervention: DFCI Protocol DFCI 81-01
Number of subjects: 897
Study 6596060 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase therapy
Number of subjects: 20
Study 6596060 — intervention group
Group type: COMPARATOR
Intervention: Intravenous streptokinase therapy (1 million IU over 20 minutes)
Number of subjects: 20
Study 30711868 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Laughter Yoga intervention (n = 23), consisting of eight sessions over four weeks
Number of subjects: 50
Study 30711868 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (n = 27)
Number of subjects: 50
Study 30711868 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Laughter Yoga intervention (n = 23)
Number of subjects: 50
Study 29479906 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab treatment in patients with exudative ARMD and POAG
Number of subjects: 60
Study 29479906 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab treatment in patients with DME and POAG
Number of subjects: 60
Study 29479906 — intervention group
Group type: COMPARATOR
Intervention: Control group (fellow eye not treated with bevacizumab)
Number of subjects: 60
Study 25562457 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐week balance‐training program
Number of subjects: 31
Study 25562457 — intervention group
Group type: COMPARATOR
Intervention: No balance training (control group)
Number of subjects: 31